GET DAILY SIGNALSWhy Is Stevanato Group (STVN) Stock Down -29.08% Today?
Key Takeaways
- STVN shares plunged roughly 29.08% to $14.00 in early trading, down from a prior-session close of $19.74.
- The move was driven by third-quarter fiscal 2026 results, which were in line with estimates, paired with a warning that GLP-1-related volumes and revenue will fall short of prior expectations in 2027.
- Management guided to "low single digits" growth next year, signaling a sharp deceleration from the 8% organic revenue growth delivered in the third quarter.
- Secondary pressures included a 12% organic decline in the Engineering segment and just 1% growth in high-value solutions.
- The company reaffirmed its full-year 2026 guidance, but the 2027 outlook overshadowed otherwise solid quarterly margins.
- Traders are now watching for analyst estimate revisions and clarity on how quickly the core biologics business can offset the GLP-1 slowdown.
- For additional detail on valuation, results, and outlook, explore Price Targets, Earnings, and Forecast pages for STVN.
- Discover automated strategies tracking moves like this one on Trending AI Robots.
Opening Summary
Stevanato Group S.p.A. (STVN), the Italian provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries, saw its shares crater on Monday. The stock tumbled about 29.08% to $14.00, compared with a prior-session close of $19.74, marking one of the steepest single-day declines for the name in recent memory. The sell-off followed the company's third-quarter fiscal 2026 report, in which results broadly matched expectations but management's outlook for 2027 — specifically a slowdown in GLP-1-related demand — spooked investors.
Third-Quarter Results Met Estimates, but the Outlook Disappointed
Stevanato Group delivered third-quarter revenue of €326.1 million, up 8% year over year on both a reported and organic basis, while adjusted EBITDA rose 14% to €88.8 million and the adjusted EBITDA margin improved 150 basis points to 27.2%. Net income increased 16% to €41.8 million. The Biopharmaceutical and Diagnostic Solutions segment grew 11% organically, helping to offset a 12% organic decline in the Engineering segment. Despite this solid headline performance, the market reaction was sharply negative, with the focus shifting almost entirely to what comes next.
GLP-1 Slowdown Weighs on 2027 Growth
The primary catalyst for the decline was management's commentary on the company's GLP-1 exposure, which represented roughly 17% to 18% of third-quarter revenue. Executives said they now expect lower GLP-1 volumes and revenue in 2027 than previously estimated, projecting that this will cause a temporary moderation of growth next year. As a result, the company anticipates only low-single-digit growth in 2027 — a meaningful step down from the current high-single-digit trajectory. Because GLP-1 therapies have been a key investor narrative for STVN, the reduced visibility triggered a broad de-rating of the stock.
Mixed Segment Signals Add to Pressure
Beyond GLP-1, the report revealed a few other areas of softness that reinforced the bearish tone. High-value solutions revenue grew only 1% year over year to €149.4 million, representing 46% of total revenue, while the Engineering segment's 12% organic decline underscored continued weakness in that more cyclical part of the business. On the positive side, demand for biologics outside GLP-1 grew more than 30%, suggesting diversification is underway — but it was not enough to reassure investors focused on the 2027 outlook. The company reiterated its full-year 2026 guidance of €1.26 billion to €1.28 billion in revenue and adjusted diluted EPS of €0.60 to €0.62.
Market Context and Trading Activity
Trading in STVN was exceptionally heavy, with the sharp intraday decline reflecting an orderly but aggressive repricing rather than a gradual drift. The move diverged from broader market action, indicating the sell-off was company-specific rather than a sector-wide or macro-driven event. The stock broke well below recent support levels established around the $19 to $20 range, leaving it near the lower end of its 52-week trading band. The magnitude of the drop underscores how sensitive the shares had become to the GLP-1 growth story heading into the report.
What Comes Next for STVN
Investors will now focus on how analysts recalibrate their estimates for fiscal 2027 and whether the company's core biologics and high-value solutions franchise can compensate for the anticipated GLP-1 shortfall. Key areas to watch include the pace of order conversion in the Engineering segment, the commercial ramp of the company's drug delivery devices, and any further updates on capacity investments and free cash flow. Risks remain concentrated in the timing and magnitude of the GLP-1 normalization, while the company's reiterated 2026 guidance provides a degree of near-term stability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies varying by approach, timeframe, performance metrics, and traded symbols. Explore the Trending AI Robots to see which automated strategies are navigating today's volatile tape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STVN's Indicator enters downward trend
The Aroon Indicator for STVN entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator formed such a pattern. In 154 of the 172 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 64 cases where STVN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
STVN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STVN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
STVN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STVN's RSI Indicator exited the oversold zone, 22 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on STVN as a result. In 80 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for STVN just turned positive on October 23, 2026. Looking at past instances where STVN's MACD turned positive, the stock continued to rise in 52 of 56 cases over the following month. The odds of a continued upward trend are 90%.
Following a +0.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 242 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. STVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.479) is normal, around the industry mean (4.877). P/E Ratio (40.286) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther
Advertisement